'Security guard' zinc is off-duty in diabetes

Jul 06, 2010

(PhysOrg.com) -- In type 2 diabetes, a protein called amylin forms dense clumps that shut down insulin-producing cells, wreaking havoc on the control of blood sugar. But in people without diabetes, amylin doesn't misbehave; it actually pitches in to help with blood sugar regulation. What accounts for the difference?

It's all about the company amylin keeps, new research by Ayyalusamy Ramamoorthy and colleagues at the University of Michigan suggests. In the presence of zinc, amylin is mild-mannered; without zinc, it runs amok. The research will appear in the July 7 issue of the .

"We found that one of the likely factors stopping amylin from attacking the insulin-producing islet cells of the pancreas is zinc, which normally is found in high amounts in these cells, but is deficient in people with ," said Ramamoorthy, U-M professor of chemistry and of biophysics. "By understanding what stops amylin from attacking in normal people, we hope we'll be able to understand how it is attacking them in people with ."

The new research suggests that in healthy cells, zinc acts like a security guard at a rock concert, whose job is keeping fans from turning troublesome and destructive. In molecular terms, zinc prevents amylin—also known as Islet Amyloid Polypeptide (IAPP)—from forming harmful clumps similar to those found in Alzheimer's, Parkinson's, Huntington's and various other degenerative diseases.

But in the zinc-starved cellular environment of someone with type 2 diabetes, amylin has no watchful guard to rein it in. It's free to band together other amylin molecules in the molecular equivalent of a gang.

Ramamoorthy and colleagues investigated zinc's role in amylin aggregation using several methods, including NMR () spectroscopy.

"We wanted to see how zinc was affecting the structure of amylin," said Ramamoorthy, "and NMR is the technique we use to do this."

The researchers obtained images of amylin with and without zinc present and saw that zinc binds to a particular side chain, disrupting the structure of amylin in the process. Other experiments showed that—at zinc concentrations typical of those found in the environment in which aggregation occurs—this binding significantly slows aggregation.

Other experiments underway in Ramamoorthy's laboratory are aimed at rounding out the picture by looking at interactions between and insulin and between insulin and amylin.

"Ultimately, we want to understand how the whole scenario leads to type 2 diabetes," Ramamoorthy said.

Explore further: Structure of sodium channels different than previously believed

More information: pubs.acs.org/journal/jacsat

Related Stories

A new metal detector to study human disease

Mar 21, 2006

Zinc may be a familiar dietary supplement to millions of health-conscious people, but it remains a mystery metal to scientists who study zinc’s role in Alzheimer’s disease, stroke and other health problems.

Recommended for you

Breakthrough points to new drugs from nature

Apr 16, 2014

Researchers at Griffith University's Eskitis Institute have developed a new technique for discovering natural compounds which could form the basis of novel therapeutic drugs.

World's first successful visualisation of key coenzyme

Apr 16, 2014

Japanese researchers have successfully developed the world's first imaging method for visualising the behaviour of nicotine-adenine dinucleotide derivative (NAD(P)H), a key coenzyme, inside cells. This feat ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

kevinrtrs
not rated yet Jul 07, 2010
Excellent work. I hope they finally get to the bottom of the actual cause of type 2 diabetes.

More news stories

Leeches help save woman's ear after pit bull mauling

(HealthDay)—A pit bull attack in July 2013 left a 19-year-old woman with her left ear ripped from her head, leaving an open wound. After preserving the ear, the surgical team started with a reconnection ...

Venture investments jump to $9.5B in 1Q

Funding for U.S. startup companies soared 57 percent in the first quarter to a level not seen since 2001, as venture capitalists piled more money into an increasing number of deals, according to a report due out Friday.